Dr Lynam on the Significance of Mirvetuximab Soravtansine in Ovarian Cancer

“[Mirvetuximab soravtansine] is truly a revolutionary agent. This was the first antibody-drug conjugate that was [FDA-]approved for use in ovarian cancer…[It] was the first in ovarian cancer to show an improvement in overall survival.”

Sarah Lynam, MD, an assistant professor in the Division of Gynecologic Oncology in the Department of Reproductive Biology at Case Western Reserve University School of Medicine, and an attending physician in the Division of Gynecologic Oncology at the Seidman Cancer Center at the University Hospitals Cleveland Medical Center, discussed the practical implications of mirvetuximab soravtansine-gynx (Elahere) for the treatment of ovarian cancer.

Mirvetuximab soravtansine is a revolutionary agent in the ovarian cancer landscape, notably because it was the first antibody-drug conjugate (ADC) FDA-approved for the treatment of patients with ovarian cancer, Lynam began. Mirvetuximab soravtansine was granted accelerated approval by the FDA in November 2022 for the treatment of patients with folate receptor α (FRα)–positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who were previously treated with 1 to 3 prior systemic treatment regimens. The regulatory decision was based on the phase 3 SORAYA trial (NCT04296890). Additionally, the FDA granted full approval to mirvetuximab soravtansine in March 2024 for the same patient population, for which the decision was supported by data from the phase 3 MIRASOL trial (NCT04209855).

Furthermore, she noted that other ADCs are beginning to emerge in the gynecologic cancer landscape, namely with the April 2024 FDA approval of tisotumab vedotin-tftv (Tivdak) for the treatment of patients with recurrent or metastatic cervical cancer who have experienced disease progression on or after receiving chemotherapy, Lynam continued. Nevertheless, she emphasized that mirvetuximab soravtansine was the first ADC in ovarian cancer to demonstrate improvement in overall survival. Having a treatment option like mirvetuximab soravtansine is a significant, particularly as the landscape moves toward more personalized and tissue-informed treatment decisions for patients with ovarian cancer, she concluded.